Enzyme revealed as promising target to treat asthma and cancer

April 10, 2014, Johns Hopkins University School of Medicine

In experiments with mice, Johns Hopkins Kimmel Cancer Center scientists have identified an enzyme involved in the regulation of immune system T cells that could be a useful target in treating asthma and boosting the effects of certain cancer therapies.

In research described online April 6 in Nature Immunology, the investigators show that mice without the SKG1 were resistant to dust mite-induced asthma. And mice with melanoma and missing the enzyme, developed far fewer lung tumors—less than half as many—than mice with SKG1.

"If we can develop a drug that blocks the enzyme in a way that mimics what happens when the enzyme is missing, we would not only have a treatment to inhibit asthma, but also a drug that could be used in conjunction with other experimental therapies aimed at helping the immune system fight ," said Jonathan D. Powell, M.D., professor of oncology at the Johns Hopkins Kimmel Cancer Center.

The unusual dual potential of an SKG1-blocking compound stems from the enzyme's role in a key pathway linked to T cells, which act as either "generals" of the immune system by directing how the system works, or "soldiers" that seek and destroy foreign cells.

Powell and his colleagues decided to look at SKG1 because it works along the same pathway of a protein called mTOR, a focus of their previous research. The mTOR pathway helps T cells decipher signals from their environment, and prompts the cells to transform into specific T cell types.

As part of this pathway, SKG1 dials down production of a signaling protein called interferon-gamma. When SKG1 is inactive, T cells produce increased amounts of interferon-gamma that appear to be useful in fighting tumor cells.

Powell said that a SKG1-blocking drug might be used in conjunction with other cancer immunotherapies as a sort of booster medication to enhance their effects. Experimental cancer immunotherapies, including vaccines and so-called checkpoint blockade inhibitors, are the focus of intense research within the past few years, he added.

The researchers also discovered that SKG1 promotes the production of T helper 2 , which become overactive in asthma and other allergies in a sort of runaway case of inflammation. Finding a drug that could shut down SKG1 could help block the inflammation that causes and other allergic reactions.

By untangling the different effects of SKG1, Powell said, his team has advanced efforts to fine-tune immune responses in patients. "We're not suppressing or exacerbating the , we're regulating it," he noted. "We're regulating it to do exactly what we want it to do."

Explore further: Investigational drug may increase survival for some patients with advanced melanoma

More information: The AGC kinase SGK1 regulates TH1 and TH2 differentiation downstream of the mTORC2 complex, www.nature.com/ni/journal/vaop … nt/full/ni.2867.html

Related Stories

Investigational drug may increase survival for some patients with advanced melanoma

March 4, 2014
An experimental drug aimed at restoring the immune system's ability to spot and attack cancer halted cancer progression or shrank tumors in patients with advanced melanoma, according to a multisite, early-phase clinical trial ...

Researchers find potential target for drug to treat allergic asthma

March 5, 2014
An enzyme that helps maintain immune system function by "throwing away" a specific protein has a vital role in controlling symptoms of allergic asthma, new research in mice suggests.

Cancer vaccine a step closer as natural killer cells are rightly activated

March 25, 2014
Vaccines work. Their widespread use has saved millions of lives. With an ageing population that is increasingly becoming a victim to cancer, a vaccine to treat it would do wonders. In a study published in Nature, scientists ...

Moffitt Cancer Center begins Phase I clinical trial of new immunotherapy

April 10, 2014
Moffitt Cancer Center has initiated a phase I clinical trial for a new immunotherapy drug, ID-G305, made by Immune Design. Immunotherapy is a treatment option that uses a person's own immune system to fight cancer. It has ...

Experimental drug shows promise for treatment-resistant leukemias

April 8, 2014
Research in mice and human cell lines has identified an experimental compound dubbed TTT-3002 as potentially one of the most potent drugs available to block genetic mutations in cancer cells blamed for some forms of treatment-resistant ...

New mechanism for unleashing immune system against cancer

April 7, 2014
A major discovery that brings a new drug target to the increasingly exciting landscape of cancer immunotherapy was published yesterday by researchers from La Jolla Institute for Allergy and Immunology and their collaborators ...

Recommended for you

Genomics reveals key macrophages' involvement in systemic sclerosis

January 18, 2018
A new international study has made an important discovery about the key role of macrophages, a type of immune cell, in systemic sclerosis (SSc), a chronic autoimmune disease which currently has no cure.

First vaccine developed against grass pollen allergy

January 18, 2018
Around 400 million people worldwide suffer in some form or other from a grass pollen allergy (rhinitis), with the usual symptoms of runny nose, cough and severe breathing problems. In collaboration with the Viennese firm ...

Researchers discover key driver of atopic dermatitis

January 17, 2018
Severe eczema, also known as atopic dermatitis, is a chronic inflammatory skin condition that is driven by an allergic reaction. In their latest study, researchers at La Jolla Institute reveal an important player that promotes ...

Who might benefit from immunotherapy? New study suggests possible marker

January 16, 2018
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments.

Researchers identify new way to unmask melanoma cells to the immune system

January 16, 2018
system, which enables these deadly skin cancers to grow and spread.

How the immune system's key organ regenerates itself

January 15, 2018
With advances in cancer immunotherapy splashing across headlines, the immune system's powerful cancer assassins—T cells—have become dinner-table conversation. But hiding in plain sight behind that "T" is the organ from ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.